Quadrant Capital Group’s Neurocrine Biosciences NBIX Stock Holding History

Quadrant Capital Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Sell	7,689 -589	-7%	-$78.2K	0.03%	561
2025 Q4	$1.17M	Buy	8,278 +20	+0.2%	+$2.9K	0.04%	465
2025 Q3	$1.16M	Buy	8,258 +636	+8%	+$86.2K	0.04%	436
2025 Q2	$958K	Sell	7,622 -359	-4%	-$41.2K	0.03%	502
2025 Q1	$883K	Buy	7,981 +5,692	+249%	+$721K	0.03%	428
2024 Q4	$312K	Sell	2,289 -23	-1%	-$2.85K	0.02%	474
2024 Q3	$266K	Sell	2,312 -46	-2%	-$6.31K	0.02%	556
2024 Q2	$325K	Buy	2,358 +252	+12%	+$34.6K	0.02%	461
2024 Q1	$290K	Buy	2,106 +31	+1%	+$4.23K	0.02%	485
2023 Q4	$273K	Buy	2,075 +78	+4%	+$8.98K	0.02%	477
2023 Q3	$225K	Buy	1,997 +765	+62%	+$80.6K	0.02%	483
2023 Q2	$116K	Buy	1,232 +405	+49%	+$39.6K	0.01%	779
2023 Q1	$83.7K	Sell	827 -478	-37%	-$49.7K	0.01%	942
2022 Q4	$156K	Buy	1,305 +367	+39%	+$43K	0.02%	566
2022 Q3	$100K	Buy	938 +601	+178%	+$61K	0.01%	696
2022 Q2	$33K	Sell	337 -58	-15%	-$5.35K	﹤0.01%	1056
2022 Q1	$37K	Buy	395 +389	+6,483%	+$33K	﹤0.01%	1050
2021 Q4	$1K	Sell	6 -184	-97%	-$16.9K	﹤0.01%	2347
2021 Q3	$18K	Buy	190 +131	+222%	+$12.4K	﹤0.01%	1298
2021 Q2	$6K	Sell	59 -47	-44%	-$4.5K	﹤0.01%	1782
2021 Q1	$10K	Buy	106 +23	+28%	+$2.41K	﹤0.01%	1501
2020 Q4	$8K	Sell	83 -215	-72%	-$20.8K	﹤0.01%	1500
2020 Q3	$29K	Sell	298 -439	-60%	-$50.8K	0.01%	826
2020 Q2	$90K	Buy	737 +32	+5%	+$3.54K	0.02%	487
2020 Q1	$61K	Buy	705 +21	+3%	+$2.06K	0.01%	789
2019 Q4	$72K	Hold	684	–	–	0.01%	1147
2019 Q3	$60K	Hold	684	–	–	0.01%	1146
2019 Q2	$56K	Buy	684 +30	+5%	+$2.46K	0.01%	1167
2019 Q1	$56K	Buy	654 +647	+9,243%	+$54.1K	0.01%	1147
2018 Q4	$0	Sell	7 -69	-91%	-$6.61K	﹤0.01%	2262
2018 Q3	$9K	Hold	76	–	–	﹤0.01%	1339
2018 Q2	$7K	Hold	76	–	–	﹤0.01%	1437
2018 Q1	$6K	Hold	76	–	–	﹤0.01%	1478
2017 Q4	$5K	Buy	+76	New	+$5.18K	﹤0.01%	1475
2017 Q1	–	Sell	-114	Closed	-$4K	–	2109
2016 Q4	$4K	Sell	114 -172	-60%	-$7.79K	﹤0.01%	1307
2016 Q3	$14K	Hold	286	–	–	0.01%	911
2016 Q2	$13K	Buy	+286	New	+$13.2K	0.01%	899
2016 Q1	–	Sell	-121	Closed	-$6K	–	1911
2015 Q4	$6K	Buy	+121	New	+$6.15K	﹤0.01%	994

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's NBIX Position: Q1 2026 in Review

Quadrant Capital Group reduced its Neurocrine Biosciences (NBIX) stake by 7.1% in Q1 2026, selling an estimated $78.2K and leaving 7,689 shares worth $1.01M. The position accounts for 0.03% of the portfolio, ranked #561.

Quadrant Capital Group first reported a position in NBIX in Q4 2015 and has held it in 38 quarters since. The position peaked at $1.17M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Quadrant Capital Group held 7,689 shares of Neurocrine Biosciences worth $1.01M as of Q1 2026.
Quadrant Capital Group sold 589 Neurocrine Biosciences shares in Q1 2026, an estimated $78.2K.
Neurocrine Biosciences made up 0.03% of Quadrant Capital Group's portfolio in Q1 2026, its #561 holding.
Quadrant Capital Group first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 38 quarters since.
Quadrant Capital Group's Neurocrine Biosciences position peaked at $1.17M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.